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Purpose. The aim of this study was to develop and test the structure of the Multiple Sclerosis Impact Profile (MSIP), and to
evaluate its reliability and validity within a large group of MS patients.
Method. Data were obtained from a postal survey of 377 patients attending the Groningen MS centre of the university
hospital and 153 patients from the MS patients’ association.
Results. Factor analysis showed that the MSIP comprised domains representing the four components of the International
Classification (ICF). The body functions component comprised two factors, which we divided into three scales: ‘muscles and
muscle movement functions’ (MMF), ‘excretion and reproductive functions’ (ERF) and ‘mental functions’ (MF). The
activities component comprised one factor, which we divided into two scales: ‘basic movement functions’ (BMF)
and ‘activities of daily living’ (ADL). The participation component comprised one factor: ‘participation in life situations’
(PLS). The environmental factors component comprised one factor: ‘environmental factors’ (EF). Four clinically relevant
‘symptom’ items were added to the questionnaire as single items. The MISP scales yielded sufficient to good internal
consistency coefficients. Analysis of the convergent, divergent and known-groups validity indicated that the MSIP measures
the physical, psychological and social impact of MS and discriminates between categories of course of disease and disease
severity.
Conclusion. The MSIP seems to be a reliable and valid ICF-based outcome measure that covers a broad range of clinically
relevant aspects of health. ICF can play an important role in measurement development and improvement of a unified and
standard language in clinical practice and research.
Keywords: Multiple sclerosis, Multiple Sclerosis Impact Profile, functional health outcome measurement, International
Classification of Functioning Disability and Health, psychometric properties
Abbreviations: DIP, Disability and Impact Profile; SF-36, Medical Outcome Study Short Form Questionnaire;
WHOQOL-BREF, World Health Organization Quality of Life-BREF; GARS, Groningen Activity Restriction Scale; IPAQ,
Impact on Autonomy and Participation Questionnaire; MSIP, Multiple Sclerosis Impact Profile
Introduction
Multiple sclerosis (MS) is a chronic, demyelinating,
neurodegenerative disorder of the central nervous
system (CNS). The onset is usually in early adult-
hood. MS is often progressive and debilitating.
Common symptoms include optic nerve dysfunction
(e.g., visual failure); sensory disturbance (e.g., facial
pain, sensory level disturbance, numbness or tingling
sensations); pyramidal tract dysfunction (e.g., in-
creased muscle tone and hyperreflexia); ataxia (e.g.,
failure of muscle control in limbs resulting in a lack
of balance and coordination, or a disturbance of
gait); double vision; bladder and/or bowel dysfunc-
tion; and sexual dysfunction [1,2]. In addition,
impairments in speech functions [3], fatigue [4],
cognitive impairments [5] and depression are often
indicated as relevant symptoms in MS. These
Correspondence: K. Wynia, MSc, University Medical Center Groningen (UMCG), Department of Health Sciences. PO Box 196, 9700 AD Groningen, The
Netherlands. Tel: þ31 (0) 50 363 3063. Fax: þ31 (0) 50 363 6251. E-mail: k.wynia@med.umcg.nl
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symptoms have a profound impact on daily function-
ing and participation in life situations.
In clinical practice and research, reliable and
validated assessment tools and outcome measures
are needed that cover this broad range of health
problems in MS patients. The International Classi-
fication of Functioning, Disability and Health (ICF)
is a classification of human functioning and disability
that can be used in the development of such
measures [6]. The overall aim of the ICF classifica-
tion is to provide a unified and standard language
and a framework for the description of health and
health-related states. The ICF enables the user to
record useful profiles of individuals’ functioning,
disability and health in various domains. The ICF
comprises four key components. The first compo-
nent, body functions and structures, refers to functions
of body systems, such as ‘sleep functions’ or ‘muscle
functions’, and to anatomic parts such as ‘structure
of brain’ or ‘structure of urinary system’. The second
component, activities, refers to ‘task or action
execution by the individual’ such as ‘washing
oneself’, ‘walking’ and ‘doing housework’. The third
component, participation, refers to ‘involvement in
life situations’ such as ‘family relationships’ and
‘work and employment’. The environmental factors
such as ‘personal care providers’ and ‘transportation
services’, which interact with these three compo-
nents, are described in the fourth component of the
ICF [6].
In the model of functioning that underlies the ICF
classification system, the components body functions
and structures, activities and participation are
summarized under the concepts ‘functioning’ and
‘disability’. These are associated both with health
status and with personal and environmental factors.
Functioning is an umbrella term encompassing all
body functions, activities and participation. Similarly
disability is an umbrella term for impairments in body
functions (e.g., impairment in muscle functions),
limitations in activities (e.g., limitations in walking)
and restrictions in participation (e.g., restriction in
family relationships) [6].
The ICF in its original form with more than 1400
categories is hardly practicable in clinical practice or
research. For assessment in clinical practice and
treatment trials ICF-based tools are required which
are tailored to the needs of the prospective users [7].
To the best of our knowledge there is no disease-
specific measure for MS, based on the broad scope of
the ICF. We therefore developed a questionnaire to
measure disability in patients with MS, based on a
selection of relevant aspects from the four ICF
components [8]. We called this questionnaire the
Multiple Sclerosis Impact Profile (MSIP).
The objective of this study is to develop and test
the structure of the MSIP, and to evaluate the
reliability and validity of this new measure within a
large group of MS patients.
The following research questions were addressed:
(1) Which items are representative for the ICF
components that are hypothesized to be
relevant for MS and do these items comprise
scales?
(2) What is the reliability of these scales?
(3) Do these scales measure MS-specific do-
mains of functioning as they purport to do?
(4) Do these scales discriminate between groups




We addressed our research questions with a cross-
sectional multi-centre study using samples of MS
patients from two studies: (i) members of the MS
patients’ association in the northern parts of the
Netherlands (PA sample). These patients partici-
pated in a study evaluating an integrated care
programme and were asked for separate consent to
participate in this study, and (ii) patients from the
Groningen MS centre, which is part of the Neurol-
ogy Department of the University Hospital (UH
sample). Eligible patients were selected from the
patient record system of the hospital. Before recruit-
ing patients from the University Hospital we
meticulously removed all patients already participat-
ing in the PA study from the sampling base, to
prevent patients from participating in both studies.
Of the 172 questionnaires sent out in the PA sample,
153 questionnaires (89% response rate) were re-
turned and used for analyses. Nineteen question-
naires (11%) were not returned. Of the 562 UH
patients, 185 (33%) dropped out due to: (i) change
of address or deceased, n¼ 82, (ii) too ill to fill out
the questionnaire, n¼ 9, and (iii) 94 questionnaires
were not returned. The remaining 377 patients (67%
response rate) completed the questionnaires. Non
responders in the PA sample did not differ in age
(t¼ 0.35; df¼ 20; p¼ 0.73) and gender (w2¼ 1,11;
df¼ 1; p¼ns) from participating patients. Similar
results were found in evaluating differences between
non responders and patients in the UH sample (age:
t¼ 1.72; df¼ 95; p¼ 0.09; gender: w2¼ 0.17; df¼ 1;
p¼ns).
Respondents in both samples completed the
MSIP, the WHOQOL-BREF and demographic
questions. Respondents in both samples filled out
two additional questionnaires (and not all four, to
prevent overloading of the respondents): respon-
dents in the UH sample also completed the GARS
































[9] and the IPAQ [10,11], while respondents in the
PA sample also completed the SF-36 and the DIP
[12,13].
The local university hospital Medical Ethics
Committee approved the research protocols of both
studies. Written informed consent from patients in
both samples was obtained.
The MSIP
We developed the MSIP as an ICF-based measure to
assess disability among MS patients in a disease-
targeted way. First, items were selected from the
complete version of the ICF by panels of patients,
proxies and health professionals [8]. Secondly, these
items were operationalized in order to estimate the
patients’ objectified opinion of the incidence and
severity of a disability, and to estimate the support
from relevant environmental factors:
(1) The ICF terminology for ‘disabilities’ was
applied when formulating the questions:
impairments in body functions, limitations in
activities and restrictions in participation.
(2) ICF item labels were used when formulating
the subject of the question (e.g., ‘urination’
functions instead of ‘bladder’ functions) to
promote a unified language.
(3) ICF codes (e.g., b280 or p920) were docu-
mented for each question.
(4) Illustrative examples were annexed to some
questions to ensure an adequate response.
As a result questions were phrased as follows:
. Body function items: ‘Do you face impairment in
your sleep functions? (b134)’
. Activity items: ‘Do you face limitations in
changing your body position? (a410)’
. Participation items: ‘Are there obstacles in your
environment that complicate your participation
in work? (p850)’
. Environmental Factor items: ‘Are social security
services supportive for you? (e570)’
To record the presence and severity of a problem
in functioning, we applied response scales with
scoring options specified for each ICF component,
based on ‘qualifier’ proposed by the ICF [14]
(Table I):
. For the body functions items we applied the
primary qualifier as a five-point scale indicating
the presence of impairment and the degree of
impairment of functioning.
. For the activity items we applied the capacity
qualifier as a four-point scale with response
options representing the need for assistive
devices or personal assistance in executing a
task or an action. Notably, during pre-testing it
became clear that there were no equal distances
between the applied response options. There-
fore we decided to skip response options 3
(‘another person’s help is necessary’) and to
label the phrasing of response option 4 with
score 3.
. For the participation items we applied the
performance qualifier as a five-point scale with
response options representing the presence and
the degree of restriction in participation in life
situations caused by obstacles in the current
environment.
. For the environmental factor items we applied a
three-point scale to denote the extent to which
Table I. Response options for each ICF component based on ICF qualifiers.
Body function component Activities component Participation component
Environmental factors
component
Generic scale Impairment Capacity limitation Performance barrier Facilitator
– – 9 I am not able to judge 9 Does not apply 9 Does not apply 9 Does not apply
0 No problem 0 No, not at all 0 No, not at all 0 No, not at all 0 Yes, very supportive
1 Mild problem 1 Yes, I have a mild
impairment
1 Yes, but assist devices
and/or adaptations are
not necessary.
1 Yes, as a consequence
I have some trouble




2 Yes, I have a
moderate
impairment




2 Yes, as a consequence
I have trouble





3 Yes, I have
a severe
impairment
3 Yes, as a consequence
I have a lot of trouble




4 Yes, I have
a complete
impairment




4 Yes, as a consequence . . . .
is (nearly) impossible.
4 No, not supportive
































an environmental factor acts as facilitator or
barrier to execute tasks or actions, or to
participate in life situations. Notably, consider-
ing the relevance and the presumed difficulty
for patients to respond more accurately, we
decided to apply a three-point scale in stead of
the suggested five-point scale for this qualifier.
The preliminary questionnaire was reviewed by
patients, clinicians, nurse specialists, experts on the
ICF and methodologists (n¼ 24) for clarity, com-
prehensiveness, redundancy and patient burden. A
modified questionnaire was pre-tested in a random
sample of three clinicians and 50 patients who were
not involved in the first appraisal of the question-
naire. Unclear or ambiguous items and instructions
were identified and modifications of the question-
naire were made. The final questionnaire used for
psychometric evaluation in this study comprised of
44 items: body functions component (14 items),
activities component (19 items), participation compo-
nent (7 items) and environmental factors component
(4 items).
Item reduction and scale construction
Using factor analysis we examined whether the
domains, measured by the MSIP, represent the four
ICF components. Principal component analysis
(PCA) with Varimax rotation was performed and
Communalities, Eigenvalues, Scree plots, explained
variance and factor loadings were examined to
determine the factor structure [15 – 17].
In order to create reliable domains, items were
selected or rejected for scale construction according
to two criteria: (i) items should correlate sufficiently
(factor loading 0.50) with the expected domain in
the data; and (ii) items correlating with more than
one factor were considered to violate the assumption
that each item should contribute exclusively to a
single hypothetical factor or domain. Thus, items
with dual factor loading 0.40 were eliminated from
further analysis.
Single items
Since all items included in the original questionnaire
were appraised as ‘very relevant’ by a large panel who
selected these items from the ICF, we decided that
items that could not meet the criteria of scalability
should be taken into consideration for use as single
indicators.
Reliability
Reliability was examined with the internal consis-
tency coefficient Cronbach’s alpha (alpha) and the
mean inter-item correlation coefficient (MICC) for
each scale [18,19]. Internal consistency refers to the
overall degree to which the items that make up a
scale are inter-correlated. However, the value of
alpha is somewhat dependent on the number of
items in the scale, whereas the degree of inter-item
correlation does not have this dependency. Alpha
was considered sufficient if 0.70 [15]. Clark and
Watson [19] recommended that the MICC should
fall in the range of 0.15 – 0.50. They suggested this
rather wide range because the optimal value will
necessarily vary with the generality versus specificity
of the target construct. If one is measuring a broad
higher order construct, a MICC as low as 0.15 – 0.20
is probably desirable, while for a valid measure of a
narrower construct, a much higher MICC (perhaps
in the 0.40 – 0.50 range) is needed [18,19]. As Clark
and Watson [19] suggest, test developers should use
a target MICC depending on their aim rather than to
try to achieve a particular value of alpha.
Missing values
The Cronbach’s alpha, in connection with the
number of items included in the scales, was used as
the criterion for restricting the number of missing
data that were allowed to be replaced [20] by the
mean score.
Convergent and discriminant validity
To test whether MSIP scales measure physical,
psychological and social domains of functioning as
they purport to measure, analysis of convergent and
discriminant validity [16,17] was performed by
examining the extent to which correlation values
between MSIP scales and concurrent measures were
consistent with hypotheses. We applied five con-
current self-report measures. The SF-36 and DIP
were selected as well-known reliable and valid
generic health-impact measures in MS [21]. The
SF-36 [22] consists of 36 items and generates eight
scales: physical functioning, role limitations caused
by physical functioning, bodily pain, vitality, general
health, social functioning, role limitations caused by
emotional problems and mental health. For each
dimension, item scores are coded, summed, and
transformed on a scale from 0 (worst health) to 100
(best health). In a previous Dutch study with MS
patients [23] the SF-36 showed satisfactory levels of
internal consistency with Cronbach’s alpha¼ 0.69 –
0.93 and test-retest reliability r¼ 0.48 – 0.87. In our
study Cronbach’s alpha¼ 0.74 – 0.96. The DIP
[12,13] consists of 39 parallel questions about
‘(dis)ability’ and ‘impact’. It contains three symptom
items and 36 items in five areas: mobility, self-care,
communication, social activities and psychological
































status. In this study only the disability scores were
used since this construct is closely associated with
the MSIP constructs. Item scores can range from 0
(no disability) to 10 (complete disability). Scores are
summed for each domain. In a previous Dutch
study with MS patients [23] the DIP showed
satisfactory levels of internal consistency with
Cronbach’s alpha¼ 0.61 – 0.92 and test-retest relia-
bility r¼ 0.61 – 0.86. In our study Cronbach’s
alpha¼ 0.75 – 0.92.
The WHOQOL-BREF was selected as a generic
measure of quality of life with a broad scope,
including environmental aspects. The WHOQOL-
BREF, abbreviation version [24] was derived from
the WHOQOL-100 version. It consists of 26 items
in four constructs: physical health, psychological
health, social relationships and environment. For
each construct, item scores were coded, summed,
and transformed on a scale from 0 (worst health) to
20 (best health). In a previous Dutch study [25] the
WHOQOL-BREF showed satisfying levels of inter-
nal consistency with Cronbach’s alpha¼ 0.66 – 0.80.
In our study Cronbach’s alpha¼ 0.63 – 0.81.
We used two domain specific measures, the
GARS (covering activity aspects) and the IPAQ
(covering participation aspects), to examine the
strength of the disease-specific MSIP activity and
participation aspects. The GARS [9] is a generic
instrument to measure disability in activities of daily
living (ADL) and instrumental activities of daily
living (IADL). It consists of 11 ADL items and
seven IADL items. A four-category response format
is used, ranging from 1 (no problem in performing
without help) to 4 (impossible to perform). Scores
are summed for each subscale. The GARS
was applied in several Dutch studies [9] and
showed strong levels of internal consistency with
Cronbach’s alpha¼ 0.74 – 0.91. In our study
Cronbach’s alpha was 0.95 and 0.97. The IPAQ
[10,11] is a generic questionnaire focusing on
person-perceived participation and autonomy. The
instrument assesses two aspects of participation: (i)
perceived participation, and (ii) the perceived
problem. In this study the perceived participation
aspect was used since this construct is closely
associated with the operational definition of parti-
cipation items in the MSIP questionnaire. The
sub-domains are autonomy indoors, family role,
autonomy outdoors and social relations. Item scores
are graded on a five-point rating scale with discrete
responses, ranging from 1 (very good) to 5 (very
poor). Scores are summed for each domain. In a
previous Dutch study with chronically ill patients
[11] the IPAQ showed satisfactory levels of internal
consistency with Cronbach’s alpha¼ 0.81 – 0.91 and
test-retest reliability r¼ 0.83 – 0.91. In our study
Cronbach’s alpha¼ 0.86 – 0.94.
Regarding convergent validity we hypothesized
that the MSIP scales would have strong correlation
(0.70) [26] with scales who cover the same
domain in concurrent measures. For example,
MSIP scales for physical health should correlate
highly with the SF-36 ‘physical functioning scale’
and the WHOQOL-BREF ‘Physical Health and
Autonomy’ scale. To support discriminant validity
we hypothesized that the MSIP scales would
correlate weakly (50.40) with scales measuring
different domains in MSIP or concurrent measures.
For example, MSIP scales for physical health would
correlate weakly with psychological health scales of
MSIP and other measures. Finally, we hypothesized
that correlations between scales from the same
measure would be higher than correlations between
scales from different measures because of mono-
method effects.
Known-groups validity
Regarding known-groups validity [16,17], we hy-
pothesized that the MSIP-scales should be able to
discriminate with statistical significance between
subgroups of respondents known to differ on
relevant clinical characteristics as ‘course of the
disease’ and ‘extent of limitations’. To create such
groups two self-report global questions were used:
(1) To assess the course of the disease, we asked
respondents ‘How did your MS develop from
onset?’. Respondents should select one of the
six descriptions reflecting a disease course.
Responses were used to create two groups:
(a) patients with relapsing remitting MS with
clearly defined relapses and periods between
relapses characterized by a lack of disease
progression; and (b) patients with progressive
MS with slowly or rapidly continuous disease
progression, with or without relapses [27].
Since these subgroups are based on self-
reports, they are similar but not equivalent to
distinctions in disease course made by a
neurologist.
(2) To assess the extent of limitations, respon-
dents were asked to answer the question ‘To
what extent are you limited due to MS?’ on a
ten-point scale with a score range from 1 (not
limited at all) to 10 (severely limited).
Respondents were divided into two groups:
a) those with a ‘lower extent of limitations’
(score 1 – 4); and b) those with a ‘higher
extent of limitations’ (score 5 – 10).
To estimate the magnitude of the difference in mean
scores between groups, Cohen’s effect size d’ (ES)
[26] for unrelated samples was calculated.

































For comparison of the samples we used T-tests for
continuous variables, Chi-square tests and Fisher
exact test when appropriate, and difference of
proportions tests [28] for comparisons with catego-
rical variables. For group comparisons in the
known-groups analysis we used one-way ANOVA
analysis. Effect sizes were calculated only for
statistically significant group differences (alpha¼
0.05) with post hoc tests (with Bonferroni correc-
tion for capitalization on chance in multiple
testing). According to Cohen’s thresholds [26] an
ES of 50.20 indicates a trivial effect, an ES of
0.20 to 50.50 a small effect, an ES of 0.50 to
50.80 a moderate effect and an ES 0.80 a large




Characteristics of both samples are presented in
Table II. Samples were similar with regards to the
following characteristics: 71% were female, mean age
was 50 years (SD 11), and 80% were married or had
a partner. The employment status showed that 62%
were partially or fully retired due to MS, and 8% had
retired due to age. Only 21% of the respondents were
partially or full-time employed. Statistically signifi-
cant differences between samples were found for two
aspects: the number of years since receiving the MS
diagnosis with an average of 11 years (SD 7) for the
PA sample and 14 years (SD 8) for the UH sample;
and the percentage of persons performing voluntary
work, which was 10% in the PA sample and 5% in
the UH sample.
Item reduction and scale construction
Factor analysis identified five factors covering the
four ICF components and reduced the original 44
items to 32 items (Table III):
. Two factors within the body functions compo-
nent explained 61.3% of the total variance and
included ten items. Clinical interpretation of
item content in the first factor led to the
decision to subdivide this factor into two scales
to be labelled ‘muscle and movement func-
tions’ (MMF) and ‘excretions and reproduc-
tive functions’ (ERF). The second factor was
labelled ‘mental functions’ (MF).
. One factor of the activities component ex-
plained 65.7% of the total variance and
included thirteen items. Interpretation of this
factor revealed items on two levels: activities
Table II. Characteristics of samples.
Variable Total sample PA sample UH sample p-value* 95% CI{
N 530 153 377
Gender
Female (%) 375 (71) 114 (75) 261 (69) 0.24*
Male (%) 155 (29) 39 (25) 116 (31)
Age
Mean (SD) 50 (11) 49 (9) 50 (12) 0.06#
Range 23 – 85 32 – 75 23 – 85
Years since MS diagnosis
Mean (SD) 13 (8) 11 (7) 14 (8) 0.000#
Range 1 – 53 2 – 30 1 – 53
Marital status (%)
Married/partnership 80 80 80 1.000*
Unmarried/widowed/divorced 20 20 20
Educational level (highest level) (%)
Primary school/vocational training 154 (29) 42 (28) 112 (31) 710.3 6.5
Secondary school/vocational training 210 (40) 59 (40) 151 (40) 710.4 7.8
Higher prof. education/vocational training 131 (25) 41 (28) 90 (24) 74.9 11.5
University 27 (5) 7 (5) 20 (5) 74.3 4.2
Employment status (%) (more answers possible)
Following a training or study programme 21 (4) 4 (3) 15 (4) 74.3 2.8
Employment (part-time or full-time) 112 (21) 30 (20) 82 (22) 79.2 5.9
Voluntary work (part-time or full-time) 33 (6) 15 (10) 18 (5) 4.0 11.0
(Partially) retired due to MS 327 (62) 95 (62) 232 (62) 78.7 9.4
Housewife/househusband 164 (31) 51 (33) 113 (30) 74.5 13.0
Retired due to age 42 (8) 9 (6) 33 (9) 72.6 7.2
*Fisher’s exact test (2-sided); #two-sample t-test; {Difference of proportions test (95% CI) [28].
































which can be labelled as ‘performing tasks or
activities of daily living’ and activities that can
be labelled as ‘movement activities’ necessary
for the performance of ‘activities of daily
living’. We labelled these two scales ‘basic
movement activities’ (BMA) and ‘activities of
daily living’ (ADL).
. One factor within the participation component
explained 54.3% of the total variance and
included five items. This factor was labelled
‘participation in life situations’ (PLS).
. One factor within the environmental factors
component explained 40.2% of the total
variance and included four items. This factor
was labelled ‘environmental factors’ (EF).
Six items were not entered in the factor analysis due
to a low prevalence (20%) [19,30]: limitations in









61.3% 65.7% 54.3% 40.2%
% explained variance Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
Muscle and movement functions (MMF)
Impairment in:
Muscle power functions 0.868 –
Sensation of muscle stiffness and muscle spasm 0.847 –
Involuntary movement functions 0.738 –
Control of voluntary movement functions 0.813 –
Excretion and reproductive functions (ERF)
Impairment in:
Defecation functions 0.632 –
Urination functions 0.740 –
Sexual functions 0.703 –
Mental functions (MF)
Impairment in:
Thought, memory and attention functions – 0.789
Emotional functions – 0.810
Sleep functions – 0.630
Basic movement activities (BMA)
Limitation in:
Maintaining body position 0.793
Changing body position 0.876
Transferring oneself 0.875
Hand and arm use 0.779
Fine hand use 0.770








Recreation and leisure 0.722
Doing housework 0.613




Family and informal social relationships 0.697
Employment 0.773




Personal care and assistance 0.542
Social security services 0.548
Health services 0.814
*Principal component analysis and Varimax rotation within ICF components; {Original 44-item version of the MSIP.
































conversation; limitations in using communication
devises; limitations in eating and drinking; limita-
tions in looking after one’s health; restrictions in the
environment in using communication devices and
restrictions in acquiring a place to live. Another
six items were excluded form scale construction
because of insufficient or dual factor loadings:
impairment in speech functions, fatigue, pain,
impairment in seeing functions, limitations in mov-
ing around using equipment (e.g., wheelchair) and
limitations in using transportation.
Single items
Four items excluding items with a high prevalence
were added to the questionnaire as single ‘symptom’
items as clinically important symptoms in MS (see
introduction): fatigue, pain, impairment in seeing
functions and impairment in speech functions.
Reliability
The internal consistency of five MSIP scales was
good (Table IV): Cronbach’s alpha ranged from 0.80
to 0.91 and mean inter-item correlation (MIIC)
ranged from 0.46 to 0.65. The ‘mental functions’
scale’s Alpha was 0.62, which was, given the
number of items and strong MIIC (0.35), sufficient.
Cronbach’s alpha of the ‘environmental factors’
scale was weak (0.49), but its MIC was sufficient
(0.19) which fits the expectations for this broad
construct. Since the MICC was sufficient, we
decided to include the environmental factors scale
in the MSIP.
The final version of the MSIP consists of 36 items
(seven scales with 32 items and four single items: see
Appendix). Validity was examined with this 36-item
version.
Convergent and discriminant validity
Table V provides evidence of convergent and dis-
criminant validity of the MSIP scales reflecting
the impact of multiple sclerosis on physical, psycho-
logical and social aspects of functioning. The
direction, magnitude and pattern of correlations are
consistent with predictions. For example, convergent
validity is supported by the strong correlation values
between the MSIP physical functioning scales
(MMF, BMA and ADL) and the SF-36 ‘physical
functioning’ scale, the DIP ‘mobility’ scale and
GARS ‘ADL’ and ‘IADL’ scales. Similarly, the
MSIP ‘participation in life situations’ scale correlates
highly with the DIP ‘social activities’ scale. Con-
vergent validity is supported by weak correlation
values found between the MSIP ‘mental functions’
scale and the SF-36 ‘physical functioning’ scale, and
the GARS ‘activities’ scales. Similarly, the MSIP
‘participation in life situations’ scale correlates
weakly with the MSIP ‘mental functioning’ scale
and the SF-36 ‘mental health’ scale. Notably,
convergent validity for the MSIP ‘mental functions’
scale with the similar ‘mental functioning’ scales was
moderate despite higher correlation values being
expected. Divergent validity for the MSIP ‘participa-
tion in life situations’ scale with physical functioning
scales was moderate despite lower correlation values
being expected. Expectations for mono-method
effects were supported in all aspects of functioning:
convergent and discriminant correlation values
between MSIP scales were higher than correlation
values between MSIP scales and scales of concurrent
measures. Unexpected were the relatively strong
correlation values found between the MSIP scales
and GARS scales. As hypothesized, the MSIP
environmental scale showed weak correlations with
all physical, psychological and social functioning
Table IV. Scale and symptom item features of the MSIP.




range Mean SD Cronbach’s a MIIC*
MSIP scales
Muscle and Movement Functions (MMF) 451 4 0 – 16 0 – 16 4.9 3.4 0.88 0.65
Excretion and Reproductive Functions (ERF) 441 3 0 – 12 0 – 12 3.6 3.0 0.80 0.54
Mental Functions (MF) 431 3 0 – 12 0 – 12 2.6 2.0 0.62 0.35
Basic Movement Activities (BMA) 536 5 0 – 15 0 – 15 4.8 4.6 0.90 0.64
Activities of Daily Living (ADL) 503 8 0 – 24 0 – 24 8.3 7.2 0.91 0.56
Participation in Life Situations (PLS) 502 5 0 – 20 0 – 18 2.9 3.5 0.81 0.46
Environmental Factors (EF) 318 4 0 – 16 0 – 16 3.5 2.7 0.49 0.19
MSIP symptom items
Speech functions 586 1 0 – 4 0 – 4 0.3 0.6 – –
Fatigue 573 1 0 – 4 0 – 4 2.0 1.0 – –
Pain 569 1 0 – 4 0 – 4 1.0 1.0 – –
Seeing functions 566 1 0 – 4 0 – 4 0.8 0.9 – –
*MICC, mean inter-item correlation.
































scales of the MSIP and concurrent measures, which
supports divergent validity. Convergent validity was
not supported: the correlation value with the generic
WHOQOL-BREF environmental scale was weak.
Known-groups validity
Known-groups validity of MSIP is supported by
confirmed expectations for group differences
(Table VI). Patients classified as having progressive
MS had statistically significantly higher scores on
MSIP scales compared with those classified as having
relapsing remitting MS. Identical results were found
between patients with a ‘higher’ or ‘lower’ extent of
limitation. Effect sizes indicating clinical relevance
were high or very high. However, the effect size for
mental function between subgroups was moderate.
In contrast with these scales, patients with progres-
sive MS or high extent of limitations showed
relatively statistically significant lower mean scores
on the environmental factors scale.
Discussion
The aim of this study was to develop an ICF-based
measure for the impact of MS, and to test the
structure, reliability and validity of this measure,
which we called the MSIP. The challenge in the
development of the MSIP was to examine the
applicability of the ICF. Based on the results in
this study we conclude that the ICF can play an
important role in measurement development and can
Table V. Convergent and discriminant validity of the MSIP.
Body functions Activities Participation
Environmental
Factors
MMF ERF MF BMA ADL PLS EF Alpha
MSIP
Muscle and Movement Functions 1 0.88
Excretion and Reproductive Functions 0.66 1 0.78
Mental Functions 0.62 0.40 1 0.62
Basic Movement Activities 0.78 0.65 0.30 1 0.90
Activities of Daily Living 0.76 0.68 0.30 0.89 1 0.91
Participation in Life Situations 0.59 0.58 0.37 0.70 0.71 1 0.81
Environmental factors 70.14 70.14 0.13 70.13 0.04 0.12 1 0.49
SF-36
Physical Functioning 70.73 70.57 70.27 70.77 70.78 70.61 0.03 0.96
Role Physical 70.46 70.40 70.50 70.44 70.48 70.48 0.03 0.86
Bodily Pain 70.44 70.34 70.49 70.44 70.49 70.42 70.05 0.91
General Health 70.31 70.32 70.46 70.36 70.35 70.36 70.13 0.79
Mental health 70.23 70.21 70.52 70.18 70.29 70.39 70.26 0.86
Role Emotional 70.27 70.22 70.47 70.25 70.31 70.45 70.21 0.90
Social Functioning 70.41 70.40 70.60 70.43 70.56 70.48 70.12 0.81
Vitality 70.38 70.35 70.45 70.33 70.35 70.38 70.09 0.74
DIP
Mobility 0.76 0.66 0.40 0.84 0.80 0.62 0.02 0.92
Self Care 0.72 0.70 0.45 0.80 0.81 0.63 0.14 0.89
Social Activities 0.61 0.64 0.53 0.72 0.77 0.73 0.22 0.84
Communication 0.50 0.50 0.51 0.60 0.61 0.55 0.11 0.75
Psychological Status 0.31 0.32 0.62 0.41 0.44 0.51 0.21 0.75
WHOQOL-BREF
Physical Health and Autonomy 70.64 70.53 70.60 70.58 70.60 70.57 70.02 0.80
Psychological Health 70.38 70.37 70.57 70.37 70.38 70.42 70.19 0.80
Social Relations 70.33 70.45 70.33 70.33 70.35 70.38 70.17 0.63
Environment 70.39 70.30 70.40 70.42 70.42 70.47 70.30 0.81
GARS
Activities of Daily Living 0.75 0.66 0.18 0.92 0.93 0.67 70.17 0.97
Instrumental Activities of Daily Living 0.74 0.64 0.29 0.85 0.87 0.66 70.18 0.95
IPAQ
Autonomy Indoors 0.64 0.64 0.39 0.73 0.72 0.66 0.04 0.94
Family Role 0.51 0.51 0.42 0.52 0.54 0.53 0.09 0.91
Autonomy Outdoors 0.68 0.68 0.42 0.67 0.71 0.69 70.03 0.89
Social Relations 0.50 0.50 0.44 0.50 0.48 0.52 0.06 0.86
MMF, Muscle and Movement Functions; ERF, Excretion and Reproductive Functions; MF, Mental Functions; BMA, Basic Movement
Activities; ADL, Activities of Daily Living; PLS, Participation in Life Situations; EF, Environmental Factors.
MSIP: n¼318 – 547; SF-36: n¼170 – 171; DIP: n¼ 142 – 147; WHOQOL-BREF: n¼490 – 511; GARS: n¼ 369 – 373; IPA: n¼364 – 374.
Italic correlations¼ expected convergent correlations. Underlined correlations¼ expected discriminant correlations.
































improve a unified and standard language in clinical
practice and research.
Results regarding the structure of the MSIP show
that the original 44-item version could be reduced
to 36 items covering seven domains of four ICF
components: ‘muscle and movement functions’
(MMF), ‘excretion and reproductive functions’
(ERF) and ‘mental health’ (MH) for the body
functions component; ‘basic movement activities’
(BMA) and ‘activities of daily living’ (ADL) for the
activities component; ‘participation in life situations’
(PLS) for the participation component; and ‘environ-
mental factors’ (EF) for the environmental factors
component. Four clinically relevant items were
applied as single ‘symptom items’ in the question-
naire: impairment in speech functions, fatigue, pain,
and impairment in seeing functions (see final 36-
item version in the Appendix).The scales of the
reduced version are internally consistent. Reliability
of the ‘environmental factors’ scale was sufficient
taking into account that the Cronbach’s alpha was
low (0.49) and the mean inter-item correlation was
sufficient (0.19) for a broad construct as the
environmental factors construct is [18].
Analysis of the convergent, discriminant and
known-groups validity indicated that the MSIP
measures the physical, psychological and social
impact of MS and discriminates between categories
of disease course and disease severity. The disease-
specific environmental factors scale correlated
weakly with the concurrent generic environmental
scale. This weak association may be explained by the
MSIP measuring a much broader environmental
construct than the WHOQOL-BREF. Furthermore,
patients with progressive MS or high extent of
limitations showed statistically significant lower
mean scores on the environmental factors scale than
patients with relapsing remitting MS or low extent of
limitations. This scale thus seems to be sensitive for
the relatively smaller need for support from social
and health services in the latter group.
This study showed some unexpected results. We
were somewhat surprised by the moderate correla-
tions for the MSIP ‘mental functioning’ scale with
similar psychological functioning scales indicating
weak convergence. The same moderate correlations
were found between the psychological functioning
scales in the concurrent measures (not in table).
Analysing the content of the scales supports this
hypothesis: some items are found in each psycholo-
gical functioning scale (e.g., mood and happiness)
while other items were specific to a measure (e.g.,
nervousness, concentration and self-esteem). These
findings may be due to psychological functioning
covering a rather broad construct, including some
cognitive functions as well. Also unforeseen were the
moderate correlations between the MSIP ‘participa-
tion in life situations’ scale and the ‘physical
functioning’ scales, where lower correlations were
expected. This is acceptable when bearing in mind
two explanations: moderate correlations indicate
related but distinct domains; and, it is reasonable
to expect persons who are limited in physical
functioning (e.g., changing body position, transfer-
ring themselves or walking) will encounter problems
in participation in social activities (e.g., visiting
family, employment, recreation). The relatively
strong correlations between the MSIP scales and
GARS scales, which did not support the expected
‘mono-method’ effect, can be explained by the
relatively large number of items in the activity scales.
The effect sizes as estimated for known-groups
difference for the MSIP ‘mental function’ scale were
moderate in the face of higher expected effect sizes.
The same results were observed for the concurrent
measures (not in table). Apparently, this finding
suggests that the impact of multiple sclerosis on
mental function is not as great as on physical and
social functioning.
The ICF proved to be a useful classification for
selecting items and it turned out to be useful in an
interdisciplinary setting [8]. Operationalization of
Table VI. Known-groups validity of the MSIP.
Relapsing remitting MS (rr-MS)
versus progressive MS (p-MS)









Mean (SD) p-value ES*
MSIP
Muscle and Movement Functions (MMF) 2.1 (2.5) 6.2 (3.2) .00 1.35 2.0 (2.0) 6.2 (3.2) .00 1.46
Excretion and Reproductive Functions (ERF) 2.1 (2.4) 4.5 (3.0) .00 0.84 1.9 (2.0) 4.4 (3.0) .00 0.93
Mental Functions (MF) 2.0 (1.8) 2.9 (2.1) .01 0.41 1.8 (1.8) 2.9 (2.0) .00 0.57
Basic Movement Activities (BMA) 1.9 (3.3) 6.2 (4.7) .00 1.00 1.2 (1.8) 6.3 (4.6) .00 1.27
Activities of Daily Living (ADL) 3.3 (4.8) 10.7 (7.3) .00 1.11 2.4 (3.0) 10.8 (7.0) .00 1.36
Participation in Life Situations (PLS) 1.4 (2.6) 4.6 (4.6) .00 0.80 0.9 (1.8) 4.8 (4.6) .00 0.98
Environmental Factors (EF) 5.0 (3.5) 3.2 (3.3) .00 0.54 4.7 (4.0) 3.3 (3.4) .02 0.40
































these items to estimate the patients’ objectified
opinion of the incidence and severity of disabilities
was a complicated process. Especially the application
of the qualifiers for each ICF component into
understandable response options that meet measure-
ment requirements was complex. Considering the
results of this study, we think that the qualifiers are
applied in an adequate way.
Future studies with the MSIP should evaluate
stability over time and responsiveness in intervention
studies. Evaluations in different settings will define
the role of MSIP in clinical practice and research.
Comparison with disease-specific multiple sclero-
sis measures, such as the Multiple Sclerosis Impact
Scale (MSIS-29) [31], the Functional Assessment of
Multiple Sclerosis (FAMS) [32] and the Multiple
Sclerosis Quality of Life (MSQoL-54) [33] are
necessary. ‘These studies may determine advantages
and disadvantages of different instruments, how they
complement each other, and provide an evidence-
based framework to guide the selection of outcome
measures for research and clinical evaluation in
Multiple Sclerosis’ [31].
This study has important implications for clinical
trials and epidemiological studies. The MSIP can be
used in cross-sectional studies to describe the impact
of multiple sclerosis on functional health. Further-
more, the availability of reliable and valid outcome
measures with a broad scope like the MSIP is crucial
for improved understanding of the impact of MS and
its relationship with other indicators of disease
activity, such as neuroimaging and neurophysiology.
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Multiple Sclerosis Impact Profile (MSIP) (final 36-item version).
MSIP Body functioning questions
Scale Response options
0¼no, not at all; 1¼ yes, I have a slight impairment; 2¼ yes, I have a moderate
impairment; 3¼ yes, I have a severe impairment; 4¼ yes, I have a complete impairment
MMF B1 Do you face loss of your muscle power functions? (b730)
MMF B2 Do you face muscle stiffness or muscle spasm? (b7800/b7801)
MMF B3 Do you face involuntary movements?
(e.g., tremors or tics) (b765)
MMF B4 Do you face decreased control and co-ordination of your movements? (b760)
ERF B5 Do you face impairment in your defecation functions?
(e.g., changes in frequency, constipation, incontinence) (b525)
ERF B6 Do you face impairment in your urination functions?
(e.g., frequency of urination, incontinence, difficulties with urination) (b620)
ERF B7 Do you face limitations in sexual relations? (b640)
MF B8 Do you face changes in your mental functions?
(e.g., the ability to think logically, the ability to memorise, the ability to concentrate) (b160/b144/b140)
MF B9 Do you face changes in your emotional functions?
(e.g., fear, depression, happiness) (b152)
MF B10 Do you face impairment in your sleep functions?
(e.g., onset of sleep, the maintenance of sleep or the quality of sleep) (b134)
SYMP B11 Do you experience fatigue?
(e.g., decreased energy and endurance) (b1300/b455)
SYMP B12 Do you experience pain? (b280)
SYMP B13 Do you face impairment in your speech functions? (b320)
SYMP B14 Do you face impairment in your seeing functions?




1¼Yes, but assistance devices and/or adaptations are not necessary
2¼Yes, and assistance devices and/or adaptations are necessary
3¼Yes, and assistance devices and/or adaptations and another person’s help are necessary.
BMA A1 Do you face limitations in maintaining your body position?
(e.g., maintaining a kneeling, standing and sitting postures) (a415)
BMA A2 Do you face limitations in changing your body position?
(e.g., moving from lying down to standing up or from standing to sitting) (a410)
BMA A3 Do you face limitations in transferring yourself?
(e.g., moving from a chair into bed; from a wheelchair into a car) (a420)
BMA A4 Do you face limitations in your fine hand use?
(e.g., picking up small objects; manipulating a keyboard) (a440)
BMA A5 Do you face limitations in your arm(s) and hand(s) use?
(e.g., pulling or pushing objects; turning or twisting knobs or handles; reaching for kitchen cupboard) (a445)
ADL A6 Do you face limitations in walking? (a450)
ADL A7 Do you face limitations in washing yourself? (a510)
ADL A8 Do you face limitations in caring for parts of your body?
(e.g., brushing teeth, clipping your nails, combing your hair, shaving) (a520)
ADL A9 Do you face limitations in dressing yourself? (a540)
ADL A10 Do you face limitations in preparing meals? (a630)
ADL A11 Do you face limitations in toileting? (a530)
ADL A12 Do you face limitations in doing housework? (a640)




1¼Yes, as a consequence I have some trouble with . . . .
2¼Yes, as a consequence I have trouble with . . . .
3¼Yes, as a consequence I have a lot of trouble with . . . . . .
4¼Yes, as a consequence . . . . is (nearly) impossible.
PLS P1 Are there obstacles in your environment that complicate your mobility inside or outside your home?
(e.g., thresholds; curbs; absence of elevators) (p460/p470)
(continued)

































PLS P2 Are there obstacles in your environment that complicate your personal care?
(e.g., you do not have the necessary assistance devices and adaptations at your disposal) (p510-p540/p630)
PLS P3 Are there obstacles in your environment that complicate the maintenance of your relationships with your closest family,
friends or relatives? (e.g., the travel distance, the attitude of others) (p740-p760)
PLS P4 Are there obstacles in your environment that complicate your participation in employment?
(e.g., an unadapted workplace, the attitude of colleagues and/or the manager) (p850)
PLS P5 Are there obstacles in your environment that complicate your participation in community, recreation and leisure?






EF EF1 Is your relationship with your immediate family supportive to you?
(e.g., partner, children, parents, brothers, sisters) (e310)
EF EF2 Is the professional care and assistance you receive supportive to you?
(e.g., unpaid care and assistance included) (e340)
EF EF3 Are the social security services supportive to you?
(e.g., income support) (e570)
EF EF4 Are the health services supportive to you?
(e.g., medical and nursing care) (e580)
MMF, Muscle and Movement Functions; ERF, Excretion and Reproductive Functions; MF, Mental Functions; BMA, Basic Movement
Activities; ADL, Activities of Daily Living; PLS, Participation in Life Situations; EF, Environmental Factors.
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